KYNTRA BIO CEO buys 2,800 shares at $7.09

Rhea-AI Filing Summary

KYNTRA BIO, INC. CEO and director Thane Wettig reported an open-market purchase of common stock. He bought 2,800 shares on May 14, 2026 at a price of $7.09 per share, increasing his direct holdings to 27,203 shares. A separate line shows 40 shares of common stock held indirectly through his spouse.

Insights

Equity ownership analyst

CEO Thane Wettig made a modest open-market share purchase.

CEO and director Thane Wettig executed an open-market purchase of 2,800 shares of KYNTRA BIO common stock at $7.09 per share. This increases his directly held stake to 27,203 shares, with an additional 40 shares reported as held indirectly by his spouse.

The transaction is classified as a non-derivative open-market purchase, which is an active buying decision rather than option exercise or compensation. The filing shows no derivative positions remaining, so this update focuses on his common stock ownership as of May 14, 2026.

Insider Trade Summary

Net Buyer: 2,800 shares

Net Buy 2 txns

Insider Wettig Thane

Role CEO

Bought 2,800 shs ($20K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,800	$7.09	$20K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 27,203 shares (Direct); Common Stock — 40 shares (Indirect, By spouse)

Key Figures

Shares purchased: 2,800 shares Purchase price: $7.09 per share Direct holdings after transaction: 27,203 shares +2 more

5 metrics

Shares purchased 2,800 shares Open-market purchase on May 14, 2026

Purchase price $7.09 per share Open-market common stock purchase

Direct holdings after transaction 27,203 shares Common stock directly owned by CEO after purchase

Indirect holdings 40 shares Common stock held indirectly by spouse

Transaction type Non-derivative open-market purchase Transaction code P on May 14, 2026

Key Terms

open-market purchase, non-derivative, indirect ownership, Form 4/A

4 terms

open-market purchase financial

"He bought 2,800 shares on May 14, 2026 at a price of $7.09 per share, increasing his direct holdings."

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

non-derivative financial

"The transaction is classified as a non-derivative open-market purchase, which is an active buying decision."

indirect ownership financial

"A separate line shows 40 shares of common stock held indirectly through his spouse."

Form 4/A regulatory

"In the latest Form 4/A, CEO Thane Wettig bought 2,800 shares of KYNTRA BIO common stock."

Form 4/A is an amended filing that corrects or updates an earlier Form 4, the mandatory report that insiders (like company executives, directors, or large shareholders) must file when their ownership stakes change. Think of it as an edited receipt showing who bought or sold stock and when; investors use it to track insider confidence, detect potential conflicts, and spot trading patterns that might signal future company prospects.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did KYNTRA BIO (KYNB) report for CEO Thane Wettig?

KYNTRA BIO reported that CEO and director Thane Wettig made an open-market purchase of 2,800 shares of common stock. The transaction occurred on May 14, 2026 at a price of $7.09 per share, increasing his direct ownership stake.

At what price did KYNTRA BIO CEO Thane Wettig buy shares in the latest Form 4/A?

In the latest Form 4/A, CEO Thane Wettig bought 2,800 shares of KYNTRA BIO common stock at $7.09 per share. This was reported as an open-market purchase, reflecting a direct acquisition of non-derivative common stock on May 14, 2026.

How many KYNTRA BIO shares does CEO Thane Wettig own after this transaction?

After the transaction, CEO Thane Wettig directly owns 27,203 shares of KYNTRA BIO common stock. The filing also reports an additional 40 shares held indirectly through his spouse, indicating a small indirect position alongside his direct holdings.

Was the KYNTRA BIO CEO’s latest transaction a buy or sell of shares?

The latest reported transaction by KYNTRA BIO CEO Thane Wettig was a buy. He executed an open-market purchase of 2,800 common shares at $7.09 per share, increasing his directly held stake according to the Form 4/A filing.

Does the KYNTRA BIO Form 4/A show any indirect ownership for CEO Thane Wettig?

Yes. Besides his direct holdings, the Form 4/A shows 40 shares of KYNTRA BIO common stock held indirectly "by spouse." This line is reported as an indirect ownership entry, separate from his primary direct position of 27,203 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/19/2026 - 03:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wettig Thane

(Last) (First) (Middle)

C/O KYNTRA BIO, INC.

350 BAY STREET, SUITE 100, #6009

(Street)

SAN FRANCISCO CALIFORNIA 94133

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KYNTRA BIO, INC. [ KYNB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
05/18/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/14/2026		P		2,800	A	$7.09	27,203	D
Common Stock								40	I	By spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This Form 4/A is being filed to correct the information in column 4 to indicate an acquisition of shares. The transaction was an open-market purchase and should have been reported as an acquisition ("A"), not as a disposition ("D"). No other changes are being made.

	/s/ John Alden, Attorney-in-Fact	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)